Scientific Publications
20Jun, 2024
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model
John A. Hey, Jeremy Y. Yu, Susan Abushakra, Jean F. Schaefer, Aidan Power, Patrick Kesslak & Martin Tolar
20Jun, 2024
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease
John A. Hey, Susan Abushakra, Kaj Blennow, Eric M. Reiman, Jakub Hort, Niels D. Prins, Katerina Sheardova, Patrick Kesslak, Larry Shen, Xinyi Zhu, Adem Albayrak, Jijo Paul, Jean F. Schaefer, Aidan Power & Martin Tolar
27Feb, 2024
The Single Toxin Origin of Alzheimer’s Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention
Martin Tolar, John Hey, Aidan Power, Susan Abushakra
14Jun, 2021
Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression
Martin Tolar, John Hey, Aidan Power, Susan Abushakra
4Dec, 2020
APOE ε4/ε4 homozygotes with early Alzheimer’s disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline
Susan Abushakra, Anton P. Porsteinsson, Marwan Sabbagh, Luc Bracoud, Joel Schaerer, Aidan Power, [...]
17Aug, 2020
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid targeting drugs for Alzheimer’s disease with potential for near term approval
Martin Tolar, Susan Abushakra, John A. Hey, Anton Porsteinsson and Marwan Sabbagh